Navigation Links
VaxGen Files Last Outstanding Periodic Report With SEC
Date:10/4/2007

Plans to Initiate Process to Re-list Common Shares

SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN) announced today that it has filed its Form 10-Q for the quarter ended June 30, 2007, thereby bringing the company current on its financial reporting obligations with the U.S. Securities and Exchange Commission (SEC).

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

Accordingly, the company initiated plans to re-list its common stock on a nationally recognized stock exchange. "We believe VaxGen and its stockholders will benefit from having the company's stock trade on the most liquid and transparent market available to the company," said Matthew Pfeffer, VaxGen's Chief Financial Officer. "We intend to aggressively pursue that goal and to re-list our stock as soon as possible."

"This filing represents an important milestone for VaxGen," said James P. Panek, VaxGen's President and Chief Executive. "I want to congratulate Matt and his team for their extraordinary diligence under very challenging conditions. Since becoming CFO in the spring of 2006, Matt has consistently met internal expectations for completing the filing of our outstanding periodic reports. I am pleased with this development because I believe that having current financial statements and a listing on a well recognized stock exchange will enhance our ability to complete a strategic transaction."

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the company's application for listing of its common stock. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 under the heading "Risk Factors" for a more detailed description of such risks. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. PCR Polymerases Application Profiles
2. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
3. Obtaining a contour map from multifiles or 3D data in DataMax
4. Successful stabilization of gene expression profiles
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Third Wave files countersuit vs. Digene in patent case
7. TomoTherapy files registration statement for IPO
8. Merge files financial reports by market opening
9. The Why Files celebrates decade of science exploration
10. Third Wave files patent suits against Digene, Chiron and Bayer
11. New Web virus could lead to lost files, extortion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ... , ... A number of new instruments have recently emerged to accommodate different ... Protein and Cell Analysis Education Webinar Series , will focus on advances in the ... future applications. , Many flow cytometers have unique capabilities and the Attune NxT ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of ... Leverage Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis ... clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part of the ... to novices as well as experienced users, attendees will gain a better understanding ... tests. , Hemostasis testing quality is determined by preanalytical variables which encompass ...
(Date:4/19/2017)... WESTMINSTER, Colo. , April 19, 2017 ... specialty finance firm that provides senior debt to ... the closing of a $20 million senior secured ... orthobiologics company engaged in the development and commercialization ... of orthopedic injuries. Cerapedics, lead product, ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
Breaking Biology News(10 mins):